Director at Kiora (KPRX) receives 25,000 stock options at $2.63 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Kiora Pharmaceuticals director Erin Parsons reported a compensation-related stock option grant. She received options to buy 25,000 shares of Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.

The options will become fully exercisable on June 10, 2027 and expire on June 10, 2036. After this grant, Parsons holds options covering 25,000 shares. This is an award, not an open-market purchase or sale of stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Parsons Erin

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 25,000 options Exercise price: $2.63 per share Underlying shares: 25,000 shares +3 more

6 metrics

Stock options granted 25,000 options Grant to director Erin Parsons

Exercise price $2.63 per share Stock option strike price

Underlying shares 25,000 shares Common stock subject to options

Vesting date June 10, 2027 Options become fully exercisable

Expiration date June 10, 2036 Option term end

Options held after grant 25,000 options Total derivative holdings reported

Key Terms

Stock Option (right to buy), 2024 Equity Incentive Plan, exercise price, Common Stock

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

2024 Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan."

exercise price financial

"conversion_or_exercise_price: 2.6300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parsons Erin

(Last)

(First)

(Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS

CALIFORNIA

92024

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.63	06/10/2026		A		25,000		06/10/2027⁽¹⁾	06/10/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.

Remarks:

	/s/ Melissa Tosca, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Kiora Pharmaceuticals (KPRX) report for Erin Parsons?

Kiora Pharmaceuticals reported that director Erin Parsons received a grant of stock options for 25,000 shares of common stock at a $2.63 exercise price. The award is part of the company’s 2024 Equity Incentive Plan and represents compensation, not an open-market trade.

How many KPRX shares are covered by Erin Parsons’ new stock option grant?

The new stock option grant to Erin Parsons covers 25,000 shares of Kiora Pharmaceuticals common stock. These options give her the right to buy those shares at $2.63 per share once vested, aligning her potential upside with future company performance over the option term.

When do Erin Parsons’ Kiora Pharmaceuticals stock options vest and expire?

Erin Parsons’ stock options become fully exercisable on June 10, 2027, giving her the right to purchase 25,000 Kiora shares at $2.63 each. The options expire on June 10, 2036, providing a long exercise window once they are vested and exercisable under the plan.

Are there any open-market buys or sells in this KPRX Form 4 filing?

No open-market buys or sells are reported in this Form 4. The filing shows a grant of stock options to director Erin Parsons as compensation. The transaction is coded as an acquisition (grant/award) with a $2.63 exercise price, rather than a market trade in existing shares.

What plan governs Erin Parsons’ Kiora Pharmaceuticals stock option grant?

Erin Parsons’ stock option grant was made under Kiora Pharmaceuticals’ 2024 Equity Incentive Plan. This plan allows the company to grant options and other equity awards to align directors’ and employees’ interests with shareholders by tying compensation to future stock performance and service.

What is Erin Parsons’ reported option holding after this KPRX transaction?

Following this transaction, Erin Parsons is reported to hold options covering 25,000 shares of Kiora Pharmaceuticals common stock directly. These options have a $2.63 exercise price, become fully exercisable on June 10, 2027, and expire on June 10, 2036 if not exercised before then.